Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Oman.
Campus
Campus

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1

Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1

Exact pathophysiology of PN is currently not understood. Based on the evolving literature, type 2 inflammation may play a role in PN.

Learn more
How is LSDs prevalence & epidemiology different in our region?

How is LSDs prevalence & epidemiology different in our region?

Learn more
Global use of RAM and Thromboprophylaxis in hospitalized patients

Global use of RAM and Thromboprophylaxis in hospitalized patients

Learn more
Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab

Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab

Learn more
Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients

Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients

This systematic review and network meta-analysis revealed that the use of low-molecular-weight heparin (LMWH) may be more effective than unfractionated heparin (UFH) in reducing incidence of deep vein thrombosis (DVT) among critically ill patients.

Learn more
LDL-C The Only Causal Risk Factor for ASCVD

LDL-C The Only Causal Risk Factor for ASCVD

Learn more
Benefit of Prophylaxis for High-Risk Surgical Patients

Benefit of Prophylaxis for High-Risk Surgical Patients

Learn more
Pompe

Pompe

Learn more
About Type 2 Inflammation – Nasal Polyps

About Type 2 Inflammation – Nasal Polyps

Learn more
Slowing of brain atrophy with Teriflunomide

Slowing of brain atrophy with Teriflunomide

Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite Multiple sclerosis.

Learn more
APSC Consensus Recommendations on Dyslipidemia

APSC Consensus Recommendations on Dyslipidemia

Learn more
Independent Risk Factors for Venous Thromboembolism

Independent Risk Factors for Venous Thromboembolism

Learn more